This summer, we finally received trial results about an important clinical question: does extended aromatase inhibitor (“hormonal”) treatment of breast cancer from 5 years to 10 years affect long-term outcomes in breast cancer survivors? Post-menopausal patients with estrogen or protesterone positive breast cancer were randomized to receive either 5 years or 10 years of aromatase… Read more »
